Nievergall, E
Reynolds, J
Kok, C H
Watkins, D B
Biondo, M
Busfield, S J
Vairo, G
Fuller, K
Erber, W N
Sadras, T
Grose, R
Yeung, D T
Lopez, A F
Hiwase, D K
Hughes, T P
White, D L
Article History
Received: 14 September 2015
Revised: 3 January 2016
Accepted: 18 January 2016
First Online: 22 February 2016
Competing interests
: JR is a Novartis Shareholder. DTY and TPH receive honoraria and research funding from Novartis Oncology, Bristol-Myers Squibb and Ariad. DLW receives research funding from Novartis Oncology, Bristol-Myers Squibb and Ariad. MB and GV are employed by CSL Limited, and SJB was employed by CSL Limited. EN, CHK, DBW, KF, WNE, TS, RG, AFL and DKH declare no conflict of interest.